An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 951 participants.
Also called NCT05013008
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose other
- Phase
- Phase 2
- Enrolled
- 951 participants
- Sponsor
- Registry
-
NCT05013008 -
2021-003053-37
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, Hong Kong SAR China, Israel, Italy, Japan, Netherlands, Portugal, Russia, Singapore, South Korea, Spain, Sweden, Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT05013008. Randomized; no masking; primary purpose other. Start 2021-08-18 (actual); primary completion 2021-12-31 (actual). Results posted on 2023-03-31.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants
- Acronym
- FIGARO-BM
- Condition
- Chronic Kidney Disease
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Finerenone (Kerendia, BAY94-8862)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct05013008- Content hash
474a8c3ffe032ff53bfe7f834fb41360ab42ced74e730c2080164cf1b53799fd